Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | AKT1 | P31749 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28091017 | 0.81 | GAA (0.96) | GAAL3MBTL1HPGDEPHX1CNR1 | |
| SCHEMBL3671016 | 0.81 | GAA (0.96) | GAAL3MBTL1HPGDEPHX1CNR1 | |
| SCHEMBL21104687 | 0.81 | GAA (0.96) | GAAL3MBTL1HPGDEPHX1CNR1 | |
| SCHEMBL3665297 | 0.81 | GAA (0.96) | GAAL3MBTL1HPGDEPHX1CNR1 | |
| SCHEMBL31630217 | 0.81 | ADRB2 (0.54) | GAAL3MBTL1AKT1ADRB2HPGD | |
| SCHEMBL11749739 | 0.80 | L3MBTL1 (0.63) | GAAL3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2551362 | 0.80 | GAA (0.68) | GAAL3MBTL1SMN1; SMN2EPHX1POLB | |
| Hydrochloric Acid SCHEMBL28720089 | 0.80 | GAA (0.93) | GAAL3MBTL1HPGDSMN1; SMN2EPHX1 | |
| SCHEMBL3668041 | 0.79 | GAA (1.00) | GAAL3MBTL1HPGDSMN1; SMN2SLC6A2 | |
| SCHEMBL22342837 | 0.79 | GAA (0.62) | GAAL3MBTL1SMN1; SMN2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970394-A | Novel cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA AS | 2011-02-09 | — | — | CN | claimed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | claimed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | claimed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | claimed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| CN-101970394-B | Novel cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA AS | 2015-05-27 | — | — | CN | disclosed |
| CN-101970394-A | Novel cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA AS | 2011-02-09 | — | — | CN | disclosed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | GAA 1308/4885L3MBTL1 4065/4885AKT1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.